Vitek to develop prion technology:
This article was originally published in Clinica
US company VI Technologies (Vitex) has entered into two agreements with Oxford University in the UK to develop products for identifying and removing prions from blood. The firm has licensed Oxford's proprietary RNA ligand technology, which is designed to selectively bind to prions. It has also signed an agreement to investigate the basic science of aptamer technology applied to the blood transfusion industry. Currently there are no diagnostic tests for prion-related diseases, says Vitex of Watertown, Massachusetts.